MoonLake Immunotherapeutics

MoonLake Immunotherapeutics

Yahoo Finance • 8 days ago

MoonLake Immunotherapeutics' CFO Sells 39K Shares

CFO Sells 39,120 MoonLake Immunotherapeutics Shares Worth ~$862,000 On June 22, Matthias Bodenstedt, Chief Financial Officer of MoonLake Immunotherapeutics (NASDAQ:MLTX), sold 39,120 common shares in an open-market transaction valued at a... Full story

Yahoo Finance • 11 days ago

MoonLake Immunotherapeutics (MLTX) Outlook Strengthens as Analysts See Major Opportunity in Hidradenitis Suppurativa

We recently compiled a list of the 10 Best Biotech Stocks to Buy According to Analysts. MoonLake Immunotherapeutics (NASDAQ:MLTX) is one of the best biotech stocks on this list. TheFly reported on June 22 that Clear Street maintained its... Full story

Yahoo Finance • 17 days ago

Why MoonLake Immunotherapeutics Stock Wilted on Wednesday

Key Points It aims to raise up to $200 million in the offering. This will support its efforts to bring its top drug candidate to market.10 stocks we like better than MoonLake Immunotherapeutics › MoonLake Immunotherapeutics(NASDAQ: MLTX)... Full story

Yahoo Finance • 18 days ago

MoonLake Immunotherapeutics prices $200M public offering of Class A shares

* MoonLake Immunotherapeutics (MLTX [https://seekingalpha.com/symbol/MLTX]) said it has priced an underwritten public offering of 9M Class A ordinary shares at $20.00 per share, along with pre-funded warrants to purchase up to 1M additio... Full story

Yahoo Finance • 19 days ago

Stocks to watch on Monday after hours: MLTX, BBY, and DPZ

[Financial chart with moving up arrow graph in stock market on blue color background] Wall Street finished Monday’s session in mixed fashion as renewed uncertainty around weekend U.S.–Iran peace negotiations pressured sentiment, while wea... Full story

Yahoo Finance • 19 days ago

MoonLake Immunotherapeutics Announces Proposed Public Offering

ZUG, Switzerland, June 22, 2026 – MoonLake Immunotherapeutics (NASDAQ: MLTX) (“MoonLake”), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory skin and joint diseases, today announced a proposed... Full story

Yahoo Finance • 19 days ago

Pre-Market Movers: TNON, ADTX, LNAI See Sharp Moves

(RTTNews) - Biotech companies are seeing significant pre-market activity this Monday. Pre-market movers give traders an early read on momentum, sentiment, and potential volatility for the trading day. Price swings before the opening bell... Full story

Yahoo Finance • 20 days ago

MoonLake Soars On Positive 52-week Data Of Sonelokimab In Hidradenitis Suppurativa

(RTTNews) - MoonLake Immunotherapeutics (MLTX), a clinical-stage biotechnology company, on Monday announced positive 52 week results from the Phase 3 registrational VELA-1 and VELA-2 clinical trials evaluating Sonelokimab in patients with... Full story

Yahoo Finance • 20 days ago

MoonLake eyes FDA filing this fall on one-year results for skin treatment

ojos de hojalata/iStock via Getty Images MoonLake Immunotherapeutics (MLTX [https://seekingalpha.com/symbol/MLTX]) on Sunday said its experimental drug sonelokimab delivered strong one-year results in two Phase 3 trials for hidradenitis s... Full story

Yahoo Finance • last month

MoonLake Immunotherapeutics (MLTX) Price Target Raised to $45 At H.C. Wainwright on FDA Progress

We recently compiled a list of the 8 Best Immunology Stocks to Buy According to Hedge Funds. MoonLake Immunotherapeutics (NASDAQ:MLTX) is among the best immunology stocks. TheFly reported on May 11 that H.C. Wainwright increased its price... Full story

Yahoo Finance • 2 months ago

MoonLake Immunotherapeutics GAAP EPS of -$0.98 misses by $0.07

* MoonLake Immunotherapeutics press release [https://seekingalpha.com/pr/20508432-moonlake-immunotherapeutics-announces-positive-outcome-from-its-final-pre-bla-meeting-with] (MLTX [https://seekingalpha.com/symbol/MLTX]): Q1 GAAP EPS of -$... Full story

Yahoo Finance • 2 months ago

MoonLake Immunotherapeutics Announces Positive Outcome from its Final Pre-BLA Meeting with the U.S. FDA and Reports First Quarter 2026 Financial Results

MoonLake conducted a positive final pre-BLA (Biologics License Application) meeting with the U.S. Food and Drug Administration (FDA), where MoonLake and the FDA aligned on submission plans and the label strategy for sonelokimab (SLK) in hi... Full story

Yahoo Finance • 3 months ago

The CEO of MoonLake Immunotherapeutics Dumped Shares Worth $2.8 Million. Should Investors Avoid the Stock?

Chief Executive Officer Jorge Santos da Silva reported the sale of 150,000 shares of MoonLake Immunotherapeutics(NASDAQ:MLTX) through multiple open-market transactions on April 10, 2026 and April 13, 2026, according to a SEC Form 4 filing.... Full story

Yahoo Finance • 3 months ago

Biotech Fund BVF Trims MoonLake Stake, Sells $63M in Shares

Key Points BVF sold 3,750,000 shares for a transaction value of approximately $62.96 million on April 2, 2026. The sale represented 78.30% of BVF's direct holdings, reducing direct ownership to 1,039,238 shares. All shares were sold from... Full story

Yahoo Finance • 3 months ago

MoonLake announces Week 40 Results from its Phase 3 Clinical Trials of Sonelokimab in Hidradenitis Suppurativa at the 2026 AAD Annual Meeting

Results from the Phase 3 VELA clinical trials in adults with moderate-to-severe hidradenitis suppurativa (HS) show that clinical responses continue to improve to Week 40, with 62% of patients treated with sonelokimab (SLK) achieving HiSCR7... Full story

Yahoo Finance • 4 months ago

Micron downgraded, Five Below upgraded: Wall Street's top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: William Blair upgraded Five Below(FIVE... Full story

Yahoo Finance • 4 months ago

Goldman Questions MoonLake Immunotherapeutics’ (MLTX) Sonelokimab Approval Odds Despite Pipeline Update

MoonLake Immunotherapeutics (NASDAQ:MLTX) is among the 12 Most Promising Small-Cap Stocks According to Wall Street Analysts.Goldman Questions MoonLake Immunotherapeutics' (MLTX) Sonelokimab Approval Odds Despite Pipeline Update MoonLake I... Full story

Yahoo Finance • 5 months ago

MoonLake Announces Positive Topline Results from its Phase 2 Clinical Trial of Sonelokimab in Axial Spondyloarthritis and Reports 2025 Financial Results

In the Phase 2 S-OLARIS clinical trial in axial spondyloarthritis (axSpA), sonelokimab (SLK) demonstrated clinically meaningful benefit with 80+% of patients achieving ASAS40 by Week 12Consistently, other clinical and imaging scores also s... Full story

Yahoo Finance • 5 months ago

Goldman Sachs Notes VELA-2 Failure, Calls MoonLake Immunotherapeutics (MLTX) a High-Risk Play

We recently compiled a list of the 20 Best Biotech Stocks Under $20 to Buy Now. MoonLake Immunotherapeutics is the next stock on our list. TheFly reported on January 14 that Goldman Sachs downgraded MLTX to Sell from Neutral and set a pri... Full story

Yahoo Finance • 7 months ago

DEADLINE ALERT for MLTX, BAX, and JHX: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders

LOS ANGELES, Dec. 15, 2025 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the d... Full story